The use of rifaximin in pre-operative period of patients with tumors of the gastrointestinal tract – a retrospective study (2013-2016)
Languages of publication
Introduction: One of the most important goals of preparing a patient for elective gastrointestinal cancer surgery is to prevent postoperative complications. The literature presents many ways to prepare for surgery, but only few sources suggest that preoperative use of rifaximin provides benefits in the form of fewer perioperative complications and reduced severity of pain during this period. Objective: The presented project is a retrospective analysis of the effectiveness of rifaximin in the prevention of perioperative complications in patients treated at the Department of General Surgery with Orthopedics and Trauma Division and Urology Division of the Ministry of Interior and Administration Hospital in Lublin, and a review of international literature in this subject. Materials and methods: A retrospective analysis of the results of preoperative use of rifaximin was performed in patients scheduled for rectal and colorectal cancer surgeries at the Department of General Surgery with Orthopedics and Trauma Division and Urology Division of the Ministry of Interior and Administration Hospital in Lublin in the period between 2013 and 2016. Patients undergoing emergency surgeries were excluded from the study. Patients were divided into 2 groups, as follows: The first group consisted of 139 patients operated on for rectal and colorectal cancer in years 2013-2015, in whom rifaximin was not used in the preoperative period. The second group consisted of 42 patients operated on in 2016, in whom rifaximin was used in the preoperative period at the dose of 2 x 2 tablets (400 mg) per day at 12-hour intervals, for 7 days before the scheduled surgery. Additionally, a probiotic was administered for 7 days. Drugs were ordained at the Oncological Outpatient Clinic as part of pre-hospitalization checks. Results: The use of rifaximin in the preoperative period in patients with colorectal cancer shortened the time of postoperative hospitalization and reduced postsurgical pain in comparison with the control group. The analysis revealed no differences in the numbers and the intensity of surgical complications in both groups. Conclusions: No large studies have been published to date on the influence of rifaximin on the development of colorectal cancer. Suggestions that rifaximin has a positive effect on the perioperative period of patients treated for colorectal cancer had been presented in isolated reports; these observations are confirmed by our retrospective analysis.
Publication order reference